The Department of Health has taken note of the Pretoria High Court judgment delivered on 20 October 2026 in the review proceedings brought by Hetero and Cipla concerning items 13 and 23 of the antiretroviral tender, HP13-2025ARV, which relate to the first-line HIV treatment regimen containing tenofovir, lamivudine and dolutegravir (TLD) combination.
The Department welcomes the Court's ruling dismissing Hetero’s review




